Abstract: The subject matter described herein is directed to stable L-cysteine compositions for injection, comprising: L-cysteine or a pharmaceutically acceptable salt thereof and/or hydrate thereof in an amount from about 10 mg/mL to about 100 mg/mL; Aluminum in an amount from about 1.0 parts per billion (ppb) to about 250 ppb; cystine in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; pyruvic acid in an amount from about 0.01 wt % to about 2 wt % relative to L-cysteine; a pharmaceutically acceptable carrier, comprising water; headspace O2 that is less than 1.0%; dissolved oxygen present in the carrier in an amount from about 0.01 parts per million (ppm) to about 1 ppm, wherein the composition is enclosed in a single-use container having a volume of from 10 mL to 100 mL. Also described are compositions for a total parenteral nutrition regimen and methods for their use.

Abstract: The present disclosure provides ionophore compounds, which are useful for facilitating delivery of a metal ion to a cell, tissue or organ of interest. The present disclosure provides compositions comprising the subject ionophore compounds. The present disclosure provides methods of delivering a metal ion intracellularly to a target cell. The present disclosure also provides methods of treating a condition associated with a metal deficiency in an individual.

Abstract: Provided herein are biocompatible and/or biodegradable hydrogel compositions comprising native collagen and chondroitin sulfate, the collagen and chondroitin sulfate being chemically cross-linked thereby forming a matrix. The native collagen may comprise recombinant human collagen type I (rHCI), recombinant human collagen type III (rHCIII), or a combination thereof, for example. Methods and uses thereof for regeneration or repair of tissue, improvement of tissue function, mechanical stabilization of tissue, prevention of tissue damage, or prevention of tissue loss of function are described, particularly with respect to cardiac tissue and myocardial infarction events.

Abstract: Disclosed herein are novel lipids and liposomal compositions prepared using such compounds and related methods of neutralizing or otherwise modifying such liposomal compositions. The lipids described herein are useful for example, as liposomal vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and the subsequent transfection of such target cells. In certain embodiments, one or more of the compounds that comprise the liposomal delivery vehicle may be neutralized or further modified such that the properties of the liposomal delivery vehicle are modified.

Abstract: The invention concerns compounds of formula (I) having antiviral activity, in particular, having an inhibitory activity on the replication of the respiratory syncytial virus (RSV). The invention further concerns pharmaceutical compositions comprising these compounds and the compounds for use in the treatment of respiratory syncytial virus infection. (Formula I).

Abstract: The present invention provides a dental adhesive material kit that exhibits high adhesive property to tooth structure and dental prosthesis through photopolymerization while maintaining good ease of handling with the paste properties that undergo little change during long storage. The present invention relates to a dental adhesive material kit comprising: an aqueous adhesive dental composition (X) comprising a radical polymerizable monomer (a) containing an acidic group, a polymerization accelerator (b), water (c), and a radical polymerizable monomer (d) containing no acidic group; and a curable dental composition (Y) comprising a hydrophilic radical polymerizable monomer (d-1) containing no acidic group, a hydrophobic radical polymerizable monomer (d-2) containing no acidic group, a chemical polymerization initiator (e), a photopolymerization initiator (f), and a filler (g), the filler (g) being a filler treated with a surface treatment agent, and having an average particle diameter of 0.01 to 50.

Abstract: The most prevalent pharmaceutical dosage forms at present, the oral-delivery tablets, are granular solids. An inherent limitation of such granular solids for drug release applications is the unpredictability of the microstructure. As a result, the drug release rate and other properties are difficult to control, and their range is also limited. Presented herein, therefore, is a solid dosage form with predictable microstructure and properties. The dosage form includes a drug-containing solid comprising a three dimensional structural framework of one or more two-dimensional structural elements or sheets.

Abstract: The present invention relates to a new process for the preparation of microcapsules. Microcapsules obtainable by said process are also an object of the invention. Perfuming compositions and consumer products comprising said capsules, in particular perfumed consumer products in the form of home care or personal care products, are also part of the invention.

Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

Abstract: The present invention relates to lipid nanoparticles for in vivo drug delivery and uses thereof, and the lipid nanoparticle are liver tissue-specific, have excellent biocompatibility and can deliver a gene therapeutic agent with high efficiency, and thus it can be usefully used in related technical fields such as lipid nanoparticle mediated gene therapy.

Abstract: Association of dry extract of feverfew, dry extract of willow and magnesium for use as an adjuvant in the prophylaxis and treatment of migraine and related oral compositions, in particular as a food supplement.

Abstract: Provided herein is an oral pharmaceutical composition, comprising a plurality of xanomeline beads having a core comprising xanomeline or a salt thereof; and a plurality of trospium beads having a core comprising a salt of trospium.

Abstract: Freeze dried active compositions are described. The compositions comprise less than 6.5% by weight water and they may be hydrated or added to end use compositions in order to yield compositions for delivering superior topical benefits to consumers.

Abstract: A polymerizable monomer, a filler (A), and a filler (B) are contained, the filler (A) includes an inorganic particle and a compound covering the inorganic particle, the filler (B) includes another inorganic particle and another compound covering the other inorganic particle, and the average particle size of the filler (B) is 20% to 550% of the average particle size of the filler (A).

Abstract: The present invention relates to transdermal delivery systems, methods and kits that include an agent to penetrate the basement membrane, a membrane of the skin previously known to be difficult to penetrate. In particular, the formulation includes a basement membrane disruptor that reversibly denatures the basement membrane of the skin. The formulation of the present invention further includes having at least one penetration agent, at least one vaso-modulator, and at least one active ingredient. In an embodiment, the penetration agent includes a solvent, a lipophilic agent, a hydrophilic agent, wherein the basement membrane disruptor, the vaso-modulator, and the active ingredient pass through the stratum corneum and epidermis. The basement membrane disruptor allows the vaso-modulator and the active ingredient pass through the basement membrane to dermis. The active ingredient, once at the dermis, is delivered locally to the tissue or systemically to the blood stream.

Abstract: The present invention relates to an improved process for the preparation of 3?,7?-dihydroxy6?-ethyl-5?-cholan-24-oic acid compound of formula-1, represented by the following structural formula: Formula-1 The present invention also relates to process for the preparation of ethylene diamine and tertiary butyl amine salts of 3?,7?-dihydroxy6?-ethyl-5?-cholan-24-oic acid which are useful in the preparation of pure 3?,7?-dihydroxy6?-ethyl-5?-cholan-24-oic acid.

Abstract: The present invention relates to high-efficiency encapsulation of hydrophilic substances in the hydrophilic space of unilamellar liposomes. High-efficiency encapsulation is achieved by the use of a polyhydric alcohol selected from propylene glycol or glycerine for dissolving the hydrophobic compounds forming the lipid bilayer of the liposomes. The invention provides unilamellar liposomes (UL) as well as a method for preparing same by way of low temperature extrusion. The invention also relates to use of these UL in the manufacturing of a medicament, a cosmetic product, a food additive or a disinfectant.

Abstract: Disclosed herein are platelet-like particles incorporating antimicrobial metallic nanoparticles. The platelet-like particles include an ultra-low crosslinked polymeric microgel and fibrin targeting moiety. The antimicrobial metallic nanoparticles can be covalently or noncovalently incorporated into the platelet-like particles. The particles are useful to stop bleeding and to promote wound healing while at the same time suppressing bacterial infections that can accompany tissue damage.

Abstract: This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.